TABLE 2.
Immunogenicity and protective efficacy in mice of GBS type III-TT conjugate vaccines prepared with type III polysaccharides of different molecular sizes
| Vaccine | Polysaccharide size (Mr)a | Concn of polysaccharide-specific IgG (μg/ml)b | No. of survived/challenged (%)c |
|---|---|---|---|
| IIIL-TT | 349,000 | 5.5 (2.4 to 6.9) | 47/47 (100) |
| IIIM-TT | 105,000 | 1.6 (0.7 to 7.7) | 51/51 (100) |
| IIIS-TT | 38,000 | 1.1 (0.01 to 2.2) | 26/44 (59) |
| Saline | 0.0 (0.0 to 0.0) | 1/47 (2) |
a
Determined by gel filtration chromatography using an S-500 HR gel filtration column.
b
Median (range) of values from five mice per group.
c
Survival of pups born to vaccinated dams. Pups were challenged with a single intraperitoneal injection of GBS strain M781 (3.9 × 105 to 7.4 × 105 CFU per pup).